Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery
New data show 22.1% weight loss at one year with consecutive Allurion Balloons, approaching weight loss surgery outcomes
Data from a study of 121 patients across 11 obesity centers treated with two consecutive, four-month Allurion Balloons showed patients achieved 22.1% weight loss on average at one year. In comparison, studies show that patients treated with 12-month endoscopic intragastric balloons achieve 15.4%1 and 16.2%2 total body weight loss*. “We believe these findings underscore the potential of the Allurion Balloon to deliver superior outcomes to other intragastric balloons, approaching those of weight loss surgery,3,4 for patients seeking effective and safe weight loss solutions,” said Dr.
Evidence from multiple studies indicates that the Allurion Balloon—a procedureless, liquid-filled balloon—has a significantly lower intolerance rate compared to 12-month endoscopic balloons (1-3% vs 14.4%)5, with an overall serious adverse event rate that averages 10 times less than other liquid-filled balloons*.
Presentations also include data from a study analyzing 1,313 conversations from patients across 26 bariatric clinics in 12 countries and
Conversations between patients and
Presentations at ASMBS also include data on the impact of digital appetite tracking and eating behaviors in Allurion Balloon Program patients.
Details of the presentations are as follows:
Title: Consecutive 4-Month Swallowable Balloon Weight Loss Surpasses Results of a Single 12-Month Endoscopic Balloon and Approaches Weight Loss Surgery Results
Presenter: Roberta Ienca, M.D., Weight Management Center,
Title: A Novel Conversational Agent Fine-Tuned for Bariatric Treatment Provides Safe and Accurate
Presenter:
Title: Digital Tracking of Hunger and Fullness Enhances Awareness of Appetite, Food Choices and Portion Sizes in Patients with a Swallowable Gastric Balloon
Presenter:
For more information about ASMBS 2024, please visit: https://asmbsmeeting.com/about/
* The Allurion Balloon was not compared in head-to-head studies with any other gastric balloons.
Sources: 1. Obes Surg. 2024;34(1):176-182. doi:10.1007/s11695-023-06953-0; 2. Obes Surg. 2021;31(12):5342-5347. doi:10.1007/s11695-021-05729-8; 3. Obes Surg. 2021;31:3833–3847. https://doi.org/10.1007/s11695-021-05394-x); 4. ANZ J Surg. 2021;91(11):2443-2446. doi:10.1111/ans.17233; 5. Obes Surg. 2021;31(12): 5342-5347.
About Allurion
Allurion is dedicated to ending obesity. The Allurion Program is a weight loss platform that features the Allurion Gastric Balloon, the world’s first and only swallowable, procedure-less intragastric balloon for weight loss, and offers access to the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers, Allurion Insights for health care providers featuring the Coach Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor and manage weight loss therapy for patients regardless of their treatment plan: gastric balloon, surgical, medical or nutritional. The Allurion Gastric Balloon is an investigational device in
For more information about Allurion and the Allurion Virtual Care Suite, please visit www.allurion.com
Allurion is a trademark of
Forward-Looking Statements
This press release may contain certain forward-looking statements within the meaning of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611432439/en/
Global Media:
PR Manager
+33 7 84 21 02 20
cdamour@allurion.com
Investors:
ICR Westwicke
(617) 877-9641
mike.cavanaugh@westwicke.com
Source: